Pyxis Oncology Inc is trading at $1.89 (6.9% down) in pre-market, pulling back after a strong multi-day rally last week.
- The move appears to reflect typical volatility and profit-taking in a high-beta small-cap biotech rather than a new fundamental catalyst.
- No fresh company-specific filings, clinical updates, or analyst calls have hit major newswires so far this morning.
- Broader U.S. equity futures are only modestly changed, suggesting the decline is driven by technical price action following recent gains.